Basilea Pharmaceutica Ltd (BSLN.XSWX) Financials
All currency values in CHF millions unless otherwise noted
Scroll
| Income Statement | DEC 2025 | DEC 2024 | DEC 2023 | DEC 2022 | DEC 2021 |
|---|---|---|---|---|---|
| Revenues | |||||
| Revenue | CHF 232 | CHF 209 | CHF 158 | CHF 148 | CHF 148 |
| Cost of Revenue | CHF 39 | CHF 39 | CHF 27 | CHF 25 | CHF 24 |
| Gross Profit | CHF 193 | CHF 170 | CHF 131 | CHF 123 | CHF 124 |
| Total Operating Expenses | CHF 142 | CHF 109 | CHF 112 | CHF 105 | CHF 121 |
| Operating Income | CHF 52 | CHF 61 | CHF 19 | CHF 19 | CHF 3 |
| Non-Operating | |||||
| Net Interest Expense | -CHF 3 | -CHF 4 | -CHF 11 | -CHF 10 | -CHF 8 |
| Income Tax Expense | CHF 6 | -CHF 17 | CHF 0 | -CHF 0 | CHF 0 |
| Net Income | |||||
| Net Income | CHF 40 | CHF 78 | CHF 10 | CHF 12 | -CHF 7 |
| Per Share Data | |||||
| Revenue Per Share | CHF 19.22 | CHF 17.25 | CHF 13.15 | CHF 12.46 | CHF 12.68 |
| EPS (Basic) | CHF 3.33 | CHF 6.42 | CHF 0.87 | CHF 1.02 | -CHF 0.58 |
| EPS (Diluted) | CHF 3.33 | CHF 5.83 | CHF 0.86 | CHF 1.02 | -CHF 0.58 |
| Shares Outstanding | 12.1M | 12.1M | 12.0M | 11.9M | 11.7M |
| Dividends Per Share | CHF 0.00 | CHF 0.00 | CHF 0.00 | CHF 0.00 | CHF 0.00 |
Basilea Pharmaceutica (BSLN.XSWX) financials: revenue, profit and margins
Basilea Pharmaceutica (BSLN.XSWX) generated about CHF 232 million in revenue and CHF 40 million in net income (a 17.3% net margin) over the trailing twelve months, growing at roughly 11.9% a year. Figures are from company filings; this is analysis, not investment advice.
Frequently asked
What is Basilea Pharmaceutica's (BSLN.XSWX) revenue?+
Basilea Pharmaceutica generated about CHF 232 million in revenue over the trailing twelve months. Revenue has grown at roughly 11.9% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Is Basilea Pharmaceutica profitable?+
Yes, Basilea Pharmaceutica reported about CHF 40 million in net income over the trailing twelve months, a net profit margin of roughly 17.3%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
What are Basilea Pharmaceutica's profit margins?+
Basilea Pharmaceutica runs a gross margin of about 83.1%, an operating margin of about 22.2%, a net margin of about 17.3%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
How fast is Basilea Pharmaceutica growing?+
Basilea Pharmaceutica's revenue has compounded at roughly 11.9% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside BSLN.XSWX's margins and free cash flow. This is analysis from company filings, not investment advice.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.